Several double blind trials have shown that indomethacin is capable of reducing left to right shunt through a persistent ductus arteriosus in preterm infants. 2 The success rate after treatment is between 60 and 80%, with a relapse rate of about 30%."5 The observation that infants treated at greater postnatal age seemed to respond less well,6 resulted in studies of early treatment either as prophylaxis given to a cohort on the basis of birth weight,7-9 or after identification of shunting with an early aortogram or contrast echocardiography.'0 Prophylactic indomethacin reduced subsequent ductal shunting, but as only 30% of a very low birthweight cohort develop an important left to right shunt, many would consider that the risk of side effects outweighs any potential benefit. Early treatment (at a mean of [2] [3] [4] [5] [6] [7] [8] [9] days, as soon as any clinical signs were detected) was associated with a reduction in the amount of oxygen needed by those weighing less than 1000 g in one study,'2 but this has not always been confirmed and one small trial has recently shown the opposite. 13 Pharmacokinetic studies have also been used in attempts to improve the response to indomethacin. These have shown that the absorption is erratic after enteral administration,'4 and that even after an intravenous dose plasma concentrations vary 20-fold and overwhelm any differences in half life and clearance related to postnatal and gestational age. '5 In general the response of the ductus and the side effects of indomethacin do not correlate well with the plasma indomethacin concentration. 16 17 Brash et al proposed a threshold of 250 ng/ml and noted that relapse occurred on about the fifth day when concentrations of indomethacin had fallen to about 50 ng/ml. ' 
